T. Rowe Price Associates’s Tourmaline Bio TRML Stock Holding History

T. Rowe Price Associates’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9,280	Closed	-$444K	–	3136
2025 Q3	$444K	Sell	9,280 -1,481	-14%	-$41.1K	﹤0.01%	2413
2025 Q2	$173K	Buy	10,761 +518	+5%	+$8.39K	﹤0.01%	2764
2025 Q1	$156K	Buy	+10,243	New	+$164K	﹤0.01%	2722
2024 Q4	–	Sell	-7,753	Closed	-$200K	–	3059
2024 Q3	$200K	Buy	+7,753	New	+$129K	﹤0.01%	2655

T. Rowe Price Associates's TRML Position: Q4 2025 in Review

T. Rowe Price Associates sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 9,280 shares — an estimated $444K sold.

T. Rowe Price Associates first reported a position in TRML in Q3 2024 and held it in 4 quarters. The position peaked at $444K in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

T. Rowe Price Associates reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
T. Rowe Price Associates sold 9,280 Tourmaline Bio shares in Q4 2025, an estimated $444K.
T. Rowe Price Associates first reported a position in Tourmaline Bio in Q3 2024 and held it in 4 quarters.
T. Rowe Price Associates's Tourmaline Bio position peaked at $444K in Q3 2025.
0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.